Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
Vincent D. de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brčić, Reinhard Büttner, Maria Gabriela O. Fernandes, Libor Havel, Maximilian J. Hochmair, Paul Hofman, Annelies Janssens, Mikael Johansson, Léon C.L.T. van Kempen, Izidor Kern, Fernando López‐Ríos, Margreet Lüchtenborg, José Carlos Machado, Katja Mohorčič, Luis Paz‐Ares, Sanjay Popat, Aleš Ryška, Phillipe Taniere, Jürgen Wolf, Ed Schuuring, Anthonie J. van der Wekken
Abstract
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.